Wells Fargo analyst Derek Archila raised the firm’s price target on Cabaletta Bio to $14 from $4 and keeps an Overweight rating on the shares. The analyst likes the risk/reward ahead of the DSG3-CAART + cyclophos + IVIG updates in 2023. The stock could double if meaningful activity on autoAbs and efficacy measures is seen.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on CABA:
